Elbohy D.El-Hamamsy M.El-Sharkawy M.Clinical pharmacyFaculty of pharmacyMSA UniversityEgypt; Clinical Pharmacy DepartmentFaculty of pharmacyAin Shams UniversityEgypt; Internal Medicine and NephrologyFaculty of MedicineAin Shams UniversityEgypt2020-01-252020-01-2520119756299https://doi.org/https://t.ly/bLgR7ScopusHyperphosphatemia induces extraskeletal calcification of soft tissue, a link found between gastric hyperacidity and hyperphosphatemia in dialysis patients. Patientsts categorized into 3 groups viz., Group I (38 Patients) control group, Group II (39 Patients) CaCo 3 with Ranitidine 150 mg and Group III (31 subjects) same dose calcium carbonate with Omeprazole 20 mg. Blood samples were collected monthly during hemodialysis sessions.Group II showed increase in serum phosphorus at 6 th months with increase in calcium-phosphorus biproduct, decreased serum calcium. Group III showed no significant change in serum calcium, phosphorus, Parathyroid hormone and calcium-phosphorus biproduct value. Co-administration of Ranitidine with calcium carbonate may aggravate hyperphosphatemia increasing the incidence of complications. Co-administration of Omeprazole with calcium carbonate may have a beneficial role in minimizing those complications in those patients.EnglishHyperphosphatemiaHypocalcemiaOmeprazoleRanitidinecalciumcalcium carbonatecalcium phosphateomeprazoleparathyroid hormonephosphateranitidineadultarticleblood analysiscalcium blood levelchronic kidney failureclinical effectivenesscontrolled clinical trialcontrolled studydisease exacerbationdrug effectdrug efficacyfemalegastric hyperacidityhemodialysishumanhyperphosphatemiamajor clinical studymaleparathyroid hormone blood levelphosphate blood leveltreatment durationArticlehttps://doi.org/